Soluble-type small-molecule CD4 mimics as HIV entry inhibitors

Area of Science:

• Medicinal Chemistry
• Virology
• Drug Discovery

Background:

• Small molecule CD4 mimics inhibit HIV-1 entry by blocking gp120-CD4 interaction.
• Existing CD4 mimics like NBD-556 have limited water solubility due to hydrophobic structures.
• Improving hydrophilicity is crucial for developing effective HIV-1 entry inhibitors.

Purpose of the Study:

• To design and synthesize novel CD4 mimics with enhanced water solubility.
• To evaluate the anti-HIV-1 activity and cytotoxicity of these new compounds.
• To explore synergistic effects with neutralizing antibodies.

Main Methods:

• Chemical synthesis of novel CD4 mimics incorporating pyridinyl groups.
• Modification of hydrophobic structures to increase hydrophilicity.
• In vitro assays to determine anti-HIV-1 activity and cytotoxicity.

Main Results:

• Synthesized CD4 mimics with pyridinyl groups exhibited increased water solubility compared to NBD-556.
• Compounds featuring a tetramethylpiperidine ring showed high anti-HIV activity and synergistic effects with antibodies.
• A specific mimic with a cyclohexylpiperidine and 6-fluoropyridin-3-yl ring demonstrated potent anti-HIV activity with no significant cytotoxicity.

Conclusions:

• Novel soluble CD4 mimics with potent anti-HIV activity have been successfully developed.
• Structural modifications can significantly enhance water solubility and maintain or improve efficacy.
• These findings provide a foundation for the development of next-generation HIV-1 entry inhibitors.